BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34597221)

  • 21. Incidental adnexal masses detected at low-dose unenhanced CT in asymptomatic women age 50 and older: implications for clinical management and ovarian cancer screening.
    Pickhardt PJ; Hanson ME
    Radiology; 2010 Oct; 257(1):144-50. PubMed ID: 20663974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory role of prohibitin in human ovarian epithelial cancer.
    Jia L; Ren JM; Wang YY; Zheng Y; Zhang H; Zhang Q; Kong BH; Zheng WX
    Int J Clin Exp Pathol; 2014; 7(5):2247-55. PubMed ID: 24966933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
    Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
    Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Total inhibin is a potential serum marker for epithelial ovarian cancer.
    Tsigkou A; Marrelli D; Reis FM; Luisi S; Silva-Filho AL; Roviello F; Triginelli SA; Petraglia F
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2526-31. PubMed ID: 17473066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HE4--a novel promising serum marker in the diagnosis of ovarian carcinoma.
    Langmár Z; Németh M; Vleskó G; Király M; Hornyák L; Bösze P
    Eur J Gynaecol Oncol; 2011; 32(6):605-10. PubMed ID: 22335019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guideline No. 403: Initial Investigation and Management of Adnexal Masses.
    Salvador S; Scott S; Glanc P; Eiriksson L; Jang JH; Sebastianelli A; Dean E
    J Obstet Gynaecol Can; 2020 Aug; 42(8):1021-1029.e3. PubMed ID: 32736853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
    Sölétormos G; Duffy MJ; Othman Abu Hassan S; Verheijen RH; Tholander B; Bast RC; Gaarenstroom KN; Sturgeon CM; Bonfrer JM; Petersen PH; Troonen H; CarloTorre G; Kanty Kulpa J; Tuxen MK; Molina R
    Int J Gynecol Cancer; 2016 Jan; 26(1):43-51. PubMed ID: 26588231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
    Lancaster JM; Sayer RA; Blanchette C; Calingaert B; Konidari I; Gray J; Schildkraut J; Schomberg DW; Marks JR; Berchuck A
    Int J Gynecol Cancer; 2006; 16(4):1529-35. PubMed ID: 16884361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Borderline epithelial ovarian tumors: what the radiologist should know.
    Flicek KT; VanBuren W; Dudiak K; Lahkman Y; Chen LW; Butler K; Menias CO
    Abdom Radiol (NY); 2021 Jun; 46(6):2350-2366. PubMed ID: 32860524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
    Ramalingam P
    Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids.
    de Bruijn HW; ten Hoor KA; Boonstra H; Marrink J; Krans M; Aalders JG
    Tumour Biol; 1993; 14(2):105-15. PubMed ID: 8392219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation.
    Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; D'argent Mathieu E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
    J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101966. PubMed ID: 33144266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
    Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
    [No Abstract]   [Full Text] [Related]  

  • 34. The serum CA-125 concentration data assists in evaluating CT imaging information when used to differentiate borderline ovarian tumor from malignant epithelial ovarian tumors.
    Shin JE; Choi HJ; Kim MH; Cho KS
    Korean J Radiol; 2011; 12(4):456-62. PubMed ID: 21852906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
    Ayhan A; Guven S; Guven ES; Kucukali T
    Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved specificity of the CA 125 enzyme immunoassay for ovarian carcinomas by use of the ratio of CA 125 to carcinoembryonic antigen.
    Wu JT; Miya T; Knight JA; Knight DP
    Clin Chem; 1988 Sep; 34(9):1853-7. PubMed ID: 2458203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer.
    Maines-Bandiera S; Woo MM; Borugian M; Molday LL; Hii T; Gilks B; Leung PC; Molday RS; Auersperg N
    Int J Gynecol Cancer; 2010 Jan; 20(1):16-22. PubMed ID: 20130498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MMP3 in Comparison to CA 125, HE4 and the ROMA Algorithm in Differentiation of Ovarian Tumors.
    Cymbaluk-Ploska A; Chudecka-Glaz A; Surowiec A; Pius-Sadowska E; Machalinski B; Menkiszak J
    Asian Pac J Cancer Prev; 2016; 17(5):2597-603. PubMed ID: 27268637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does Human Epididymis Protein 4 (HE4) Have a Role in Prediction of Recurrent Epithelial Ovarian Cancer.
    Innao P; Pothisuwan M; Pengsa P
    Asian Pac J Cancer Prev; 2016; 17(9):4483-4486. PubMed ID: 27797265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.
    Simmons AR; Baggerly K; Bast RC
    Oncology (Williston Park); 2013 Jun; 27(6):548-56. PubMed ID: 23909069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.